SK Biopharm, Epilepsy New Drug 'Cenobamate' Expands in North American Market
[Asia Economy Reporter Gong Byung-sun] SK Biopharm announced on the 23rd that it has signed a contract with Endo Ventures for the commercialization of the epilepsy drug 'Cenobamate' in the Canadian region.
Hot Picks Today
"How Much Will They Get?" 600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division's 'Three Wallets Under One Roof'
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Yeouido's First Management Approval: Daegyo Apartment Sets Fastest Record at 2 Years 4 Months...Construction to Begin Next Year [Real Estate AtoZ]
- "Disappointing Results: 80% of Sunscreens Found Lacking in Safety and Effectiveness"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The total technology export amount is 43.3 billion KRW, and the contract period is 12 years from the initial sales date. The contract period can be extended by 3 years each time upon mutual agreement of both companies.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing Deeply for Your Vote Really Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
